Affiliation: University Hospital Aintree
- Conus peptides and neuroprotectionChristine E Heading
Department of Biological Sciences, The Open University, Milton Keynes, UK
Curr Opin Investig Drugs 3:915-20. 2002..The poor pharmacokinetic profile of the peptides remains a challenge...
- Siramesine H LundbeckC Heading
Curr Opin Investig Drugs 2:266-70. 2001..Phase III trials are expected to take place in 2002 . A series of compounds have been synthesized by Lundbeck, the most potent of which may serve as a backup compound ...
- Recent advances against substance abuseChristine E Heading
The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes, MK7 6AA, UK
IDrugs 6:681-7. 2003..For cocaine abuse, the main focus is on products targeting the dopamine reuptake system...
- NicVAX (Nabi Biopharmaceuticals)Christine E Heading
The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes MK7 6AA, UK
IDrugs 6:1178-81. 2003..Nabi Biopharmaceuticals is developing NicVAX, a proprietary vaccine designed as a potential therapeutic to prevent and treat nicotine addiction...
- Conus toxins: targets and propertiesChristine E Heading
The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes, MK7 6AA UK
IDrugs 7:1011-6. 2004..In turn, this presents problems of bioavailability, while the potency is a potential source of toxicity...
- Vivitrex (Alkermes/Cephalon)Christine E Heading
Faculty of Science, The Open University in the North, Eldon House, Regent Centre, Gosforth, Newcastle upon Tyne NE3 3PW, UK
Curr Opin Investig Drugs 7:81-8. 2006..Alkermes and Cephalon are currently awaiting Food and Drug Administration review of the Vivitrex new drug application, which was granted Priority Review in May 2005...
- Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addictionChristine E Heading
The Open University in the North, Faculty of Science, Eldon House, Regent Centre, Gosforth, Newcastle upon Tyne NE3 3PW, UK
Curr Opin Investig Drugs 8:71-7. 2007..A phase II trial was initiated in Switzerland in January 2005 and in February 2006, Cytos Biotechnology announced that it planned to begin a phase IIb/III trial in 2007...
- Gender issues and the pharmacotherapy of substance abuseChristine E Heading
Faculty of Science, The Open University in the North, Eldon House Regent Centre, Gosforth, Newcastle upon Tyne, NE3 3PW, UK
IDrugs 11:428-32. 2008..Some gender differences will have more clinical significance than others, but any difference related to gender has the potential to complicate clinical trials and other studies...